Luke Meininger
Hematology & Oncology · Tacoma, WANPI 1568813897
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations.
Across 57 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$163
- AstraZeneca$139
- Sanofi$138
- Bristol Myers Squibb$92
- Incyte Corporation$76
- AbbVie$76
- plus $605 from 21 others
What the payments were for
- Food & beverage$1,291100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 7 | $163 |
| AstraZeneca(2 entities) | 7 | $139 |
| Sanofi | 4 | $138 |
| Bristol Myers Squibb | 4 | $92 |
| Incyte Corporation | 4 | $76 |
| AbbVie | 3 | $76 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $62 |
| Mirati Therapeutics, Inc. | 2 | $54 |
| Morphosys, US Inc. | 2 | $47 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Amgen | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Gilead | 1 | $26 |
| Seagen Inc. | 1 | $24 |
| Coherus Oncology, Inc. | 1 | $23 |
| Sobi, Inc | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Epizyme, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Merck | 1 | $18 |
| GSK | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Exelixis Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $14 |
How this compares
$1,291 in reported general payments places this provider in the 55th percentile of 349 hematology & oncology providers in Washington.
Other hematology & oncology in Tacoma
- Jorge ChavesTacoma$27K
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Thomas BoydSpokane$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.